Mene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca
The rate of change across healthcare is more rapid than ever before and although 2020 has been challenging, it has forced us to think progressively about how we enable and execute the discovery and development of the next wave of life-changing medicines to patients. Because of the investment we have been making in transformative technologies, digital health solutions, and data science and AI in clinical trial innovation, we have enabled existing trials to continue safely and at speed through remote data collection from home. Scientists in our labs have rapidly applied their expertise in diagnostics, high-throughput screening and infectious diseases, developing new treatments and preventative approaches to combat the virus. This has shown how we can adapt quickly, work seamlessly across partners and accelerate the introduction of new ways of working to fast-forward the pace of science. Creating R&D organizations that are integrated and collaborative means we are fit for the future – whatever that may hold – and it is this strength which allows us to continue transforming science to create the greatest and swiftest impact on the diseases we aim to treat, prevent and in the future even cure.